Keywords: Palladin, Somaxon, Sillenor, Insomnia, Ex-US rights, Equity stake

Paladin buys ex-US rights to Somaxon’s insomnia drug Silenor for up to $129 million

Article | 13 June 2011

Print This

US drugmaker Somaxon Pharmaceuticals (Nasdaq: SOMX) has entered into an exclusive collaboration with Canada’s Paladin Labs (TSX: PLB) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in